Eli Lilly (LLY) Stock Trades Up, Here Is Why

What Happened?

Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3.1% in the afternoon session after reports of significant insider buying by top executives, including the CEO, sent the stock rebounding from a recent selloff. 

The move came after regulatory filings on Tuesday revealed that several top executives, including CEO David Ricks, had purchased nearly $2.9 million worth of company stock. Ricks alone acquired over $1 million in shares, a move investors often interpret as a strong vote of confidence from leadership. This buying activity follows a significant selloff last week, where the stock dropped about 14% due to disappointing trial data for an oral obesity pill. The insider purchases are seen as a signal that management considers the stock undervalued after the recent decline and believes the market overreacted, providing a catalyst for Wednesday's rebound.

After the initial pop the shares cooled down to $659.43, up 3.1% from previous close.

Is now the time to buy Eli Lilly? Access our full analysis report here, it’s free.

What Is The Market Telling Us

Eli Lilly’s shares are not very volatile and have only had 9 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful, although it might not be something that would fundamentally change its perception of the business.

The previous big move we wrote about was 2 days ago when the stock gained 3.1% on the news that the stock rebounded following a decline the previous week. The stock had dropped sharply the previous week after the company released its Q2 2025 earnings report. Although the company beat earnings and revenue expectations and raised its full-year guidance, the positive news was overshadowed by disappointing trial data for its oral weight-loss drug, orforglipron. The drug's trial results showed a weight loss of about 12%, which fell short of analyst expectations and the performance of some rival treatments. The current upward movement can be seen as a "buy the dip" opportunity as investors are likely re-evaluating the stock's long-term potential.

Eli Lilly is down 15.2% since the beginning of the year, and at $659.43 per share, it is trading 31.3% below its 52-week high of $960.02 from August 2024. Investors who bought $1,000 worth of Eli Lilly’s shares 5 years ago would now be looking at an investment worth $4,383.

Do you want to know what moves the business you care about? Add them to your StockStory watchlist and every time a stock significantly moves, we provide you with a timely explanation straight to your inbox. It’s free and will only take you a second.